{
  "ticker": "JNJ",
  "content": "**Report Generated:** January 13, 2026  \n**Next Refresh:** April 14, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Johnson & Johnson (JNJ) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nJohnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, ranked No. 42 on the 2024 Fortune 500 list of the largest United States corporations. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato.\n\nAt Johnson & Johnson, \"health is everything\" - their strength in healthcare innovation empowers them to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.\n\nThe company's business is divided into two business segments: Innovative Medicine and MedTech. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Johnson & Johnson began the separation of their consumer healthcare business segment in November 2021, with the consumer products business spinning off as Kenvue in 2023.\n\n## 2. Current Market Data\n\nAs of January 12, 2026, JNJ stock is trading at $207.94, up 1.74% or +$3.55. The market capitalization stands at approximately $495.7 billion. The 52-week high for Johnson & Johnson Stock is $215.18 and the 52-week low is $140.68. The dividend yield (TTM) is 2.51% with quarterly dividends of $1.30 per share.\n\nKey financial metrics include:\n- Trailing P/E: 20.03, Forward P/E: 18.02\n- Revenue (ttm): $92.15B, Net Income: $25.12B\n- Return on Equity (ttm): 33.62%, Profit Margin: 27.26%\n\n## 3. Existing Products/Services\n\n### Innovative Medicine\nThe Innovative Medicine segment drives growth through key products including Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine).\n\n**Oncology Portfolio (Leading performer):**\n- Darzalex became the company's first brand to surpass $3 billion in sales in a single quarter (Q4 2024), with year-over-year sales growing nearly 20 percent to reach $11.7 billion.\n- Erleada sales were up 25.6 percent to nearly $3 billion\n- Carvykti, a chimeric antigen receptor (CAR)-T-cell therapy for treating relapsed/refractory multiple myeloma\n\n**Immunology:**\n- Stelara fell 4.6 percent to $10.4 billion, a decline attributed to inventory dynamics and share loss as a result of EU biosimilar entrants\n- Tremfya had much better results, growing nearly 17 percent to $3.7 billion in sales\n\n**Neuroscience:**\n- Spravato is helping the segment along, as the drug grew 56 percent YoY to hit $1.1 billion\n\n### MedTech Division\nThe MedTech segment provides electrophysiology products, heart recovery portfolio, circulatory restoration products, neurovascular care, orthopaedics portfolio, surgery portfolios, contact lenses under the ACUVUE brand, and TECNIS intraocular lenses for cataract surgery.\n\nKey franchises:\n- Surgery and Orthopaedics franchises together generated $19 billion, with Orthopaedics grossing $9.16 billion and Surgery bringing in $9.84 billion\n- Vision franchise increased fiscal 2024 revenue 1.5% to $5.14 billion\n\n## 4. Planned Products/Services/Projects\n\n### Pipeline Developments\nSignificant pipeline progress including RYBREVANT + LAZCLUZE overall survival data, initiation of TAR-200 submission, and approval of investigational device exemption for the general surgery robotic system, OTTAVA.\n\n**Robotic Surgery:**\nJ&J MedTech provided an update on its long-awaited robotic system for general surgery, named OTTAVA. In November, the organization stated it would be submitting an investigational device exemption application to the U.S. FDA in the second half of 2024 to initiate clinical trials.\n\n**Digital Platforms:**\nIn 2024, Johnson & Johnson MedTech released Polyphonic, a digital surgical platform featuring surgery planning, surgical video, and telepresence services for laparoscopic surgeries.\n\n**Manufacturing Expansion:**\nJohnson & Johnson is planning a major U.S. expansion, announcing it will spend $55 billion over the next four years on manufacturing, research and development and technology in its domestic market. The investments will support three advanced manufacturing facilities and expansion of other sites.\n\n## 5. Growth Strategy\n\nJ&J executives expect the company to be positioned for a CAGR of 5-7 percent CAGR through 2030 and beyond. Company issues guidance for 2025 with operational sales growth of 2.5% - 3.5% and adjusted operational EPS of $10.75 - $10.95.\n\n**Strategic Focus Areas:**\n- The markets where the company will mostly focus include interventional cardiovascular, robotics and digital\n- CEO Joaquin Duato is laser-focused on fortifying the company's position as an \"innovation powerhouse\" by making significant advancements across its pipeline and investing in American manufacturing\n- The foundation of Johnson & Johnson's acquisition strategy is an active and continuous reshaping of its entire portfolio, strategically divesting slower-growth assets to unlock capital and management focus for redeployment into higher-growth opportunities\n\n## 6. Current and Potential Major Clients\n\nJohnson & Johnson distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson operates in over 60 countries, with its products accessible in more than 175 nations. Geographically, just over half of total revenue is generated in the United States.\n\nThe analysis reveals J&J's diversified portfolio strength, with roughly balanced geographic exposure between the US (56.6%) and international markets (43.4%).\n\n## 7. Financial Data & Performance\n\n**2024 Full Year Results:**\n2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9% and adjusted operational growth of 5.4%. 2024 Full-Year Earnings per share (EPS) of $5.79 and Adjusted EPS of $9.98.\n\n**Q4 2024 Performance:**\n2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7% and adjusted operational growth of 5.7%.\n\n**Business Segment Performance:**\n- The Innovative Medicine business unit reported $57 billion in sales and received 27 product approvals in major markets. 2024 operational sales within this unit, excluding the COVID-19 vaccine, grew 7.5 percent.\n- J&J's oncology segment was up 17.7 percent with reported sales of $20.8 billion in 2024\n\n**Cash Flow and Financial Health:**\nThe company's financial health, demonstrated by the generation of approximately $14 billion in free cash flow in the first three quarters of 2025\n\n## 8. Market Shares\n\nAs of Q2 2025, Johnson & Johnson held a substantial 14.11% market share within the Major Pharmaceutical Preparations Industry, demonstrating its leading position among key competitors. A significant portion of sales originates from products holding the #1 or #2 global market share.\n\n**R&D Investment:**\nThe company's significant investment in Research & Development (R&D) is a key driver, with the Innovative Medicine segment allocating $13.53 billion to R&D in 2024, representing 23.7% of its sales.\n\n## 9. Comparison to Competitors\n\nJohnson & Johnson is the world's largest and most diverse healthcare firm. Key competitors in 2024 include Pfizer, Merck & Co., and Procter & Gamble.\n\n**Competitive Advantages:**\nJohnson & Johnson's competitive advantages are built on a foundation of proprietary technologies and a strong intellectual property portfolio. This commitment fuels a robust innovation pipeline, leading to new product developments and technological advancements.\n\nJ&J's performance offers a benchmark for other diversified healthcare companies navigating product LOEs and seeking to innovate in rapidly evolving medical fields. Its ability to leverage integrated capabilities across medicine and medtech provides a unique competitive advantage.\n\n## 10. Partnerships, Mergers and Acquisitions\n\n**2024-2025 Major Acquisitions:**\n- In January 2025, Johnson & Johnson announced it would acquire neurological drug maker Intra-Cellular Therapies for $14.6 billion, bolstering J&J's neuroscience portfolio\n- Johnson & Johnson's most recent acquisition - Halda Therapeutics is a Developer of precision therapeutics for cancer treatment. Johnson & Johnson acquired it in November 2025 for a price of $3.05B\n- Johnson & Johnson announced several acquisitions in 2024: Ambrx Biopharma for $2 billion (in January), Shockwave Medical for $13.1 billion (in April), and Proteologix for $850 million (in May)\n\n**Strategic Rationale:**\nThe potential Protagonist acquisition is a perfect, real-time case study of the company's disciplined M&A playbook. This is not a speculative move on an unknown technology but the logical culmination of a long-term, successful partnership with Johnson & Johnson collaborating with Protagonist for years to develop icotrokinra.\n\n## 11. Recent Developments\n\n**January 2026:**\n- Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company's common stock\n- Johnson & Johnson is going to release the next earnings report on Jan 21, 2026\n\n**Recent Pipeline Progress:**\nPositive trial findings for Rybrevant and Lazcluze in lung cancer, regulatory progression for TAR-200 in bladder cancer, and CE Mark clearance for the OTTAVA robotic surgical system marked pipeline developments throughout the year\n\n**Manufacturing Investment:**\nProgress continues in the construction of the Wilson, North Carolina facility, which will employ more than 500 people when fully operational and create approximately 5,000 construction jobs during the site development\n\n## 12. AI Investment Rating & Fair Value Assessment\n\n### Investment Rating: 8/10 (Strong Buy)\n\n**Rationale for Rating:**\n\n**Strengths Supporting High Rating:**\n1. **Diversified Portfolio Excellence**: JNJ maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat\n\n2. **Financial Performance**: 2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9% and strong profitability metrics\n\n3. **Pipeline Strength**: 10+ assets having the potential to deliver over $5 billion in operational peak year sales, including five assets highlighted during the 2021 Pharmaceutical Business Review\n\n4. **Strategic Acquisitions**: Recent acquisitions like Intra-Cellular Therapies ($14.6B) and Halda Therapeutics ($3.05B) strengthen core therapeutic areas\n\n5. **Market Leadership**: Johnson & Johnson held a substantial 14.11% market share within the Major Pharmaceutical Preparations Industry\n\n**Moderate Risk Factors:**\n1. **Biosimilar Competition**: The impact of STELARA biosimilar competition will be a significant factor in 2025\n2. **Geographic Headwinds**: Geopolitical and macroeconomic challenges in Asia Pacific, particularly China, will continue to exert pressure on MedTech growth\n\n### Fair Value Estimate: $225-240\n\nBased on current analyst consensus and fundamental analysis:\n- Analyst consensus 12-month stock price target is $209.27\n- Current trading price: $207.94\n- **Conservative estimate**: $225 (8% upside)\n- **Optimistic estimate**: $240 (15% upside)\n\n**Valuation Support:**\n- Forward P/E of 18.02 appears reasonable for growth prospects\n- Strong dividend yield provides income component\n- Expected CAGR of 5-7% through 2030 supports premium valuation\n- Diversified revenue streams reduce risk compared to single-segment competitors\n\nThe combination of strong fundamentals, pipeline depth, strategic acquisitions, and market position supports a Strong Buy recommendation with moderate upside potential for growth-oriented portfolios seeking exposure to healthcare innovation.",
  "generated_date": "2026-01-13T07:15:11.335734",
  "next_refresh_date": "2026-04-14T07:15:11.335734",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.40427910000000006,
  "tokens": {
    "input": 196,
    "output": 4731,
    "cache_creation": 67014,
    "cache_read": 271412
  }
}